Vaccines and therapeutics
In an effort to slow and eventually stop the spread of the virus, the NRC is working with partners to advance research and technology development for therapies and vaccines to treat and prevent COVID-19.
Quest for a vaccine: NRC researchers mobilize to advance technologies against COVID-19
As the global pandemic continues, scientists around the world are working at breakneck speed in an effort to develop safe and effective vaccine candidates against COVID-19.
Nanotechnology Research Centre joins COVID-19 Consortium
The NRC has joined a consortium of institutions that are merging supercomputing resources to use high-end computing power to study COVID-19.
NRC's publication on COVID-19 garners worldwide attention
Experts at the Nanotechnology and Human Health Therapeutics research centres recently published a highly consulted article on the impact that the SARS-CoV-2 infection has on the central nervous system (CNS).
Funding domestic vaccine candidates as part of the GoC's COVID-19 response
On October 23, 2020, the Prime Minister announced an investment of over $23 million through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support Canadian companies responding to COVID- 19.
New made-in-Canada research tool in the fight against COVID-19
The NRC's spike protein reference material is now available for the Canadian research community. This high-quality spike protein antigen can be used for COVID-19 R&D, testing and vaccine development.
Producing lipid nanoparticle technology for vaccine delivery (Acuitas Therapeutics)
Vancouver-based Acuitas Therapeutics is a private biotechnology company that works with partners to develop therapeutics to address unmet clinical needs. The company specializes in the development of lipid nanoparticle (LNP) technology – a key component of vaccine delivery that protects messenger RNA (mRNA) and ensures it is delivered inside human cells to help fight viruses.